Jon is a Vice President of CMC at Pipeline Therapeutics. Previously, he was executive director of Chemistry at Inception Sciences, Inc., where he led CMC activities as well as medicinal chemistry in various programs from hearing restoration to immuno oncology. Prior to joining Inception, Jon led the medicinal chemistry team that discovered the LPA1R antagonist for the treatment of various fibrotic diseases including idiopathic pulmonary fibrosis (IPF) and led to the acquisition of Amira Pharmaceuticals by Bristol-Myers Squibb. He began his career as a Research Fellow at Merck & Co., Inc. where he contributed to early-stage CNS drug discovery. He was a postdoctoral fellow at California Institute of Technology with Nobel laureate Bob Grubbs and received a Ph.D. in organic chemistry from the University of California at San Diego.
« Go Back